AU2020236023A1 - Methods of treating organic acidemias - Google Patents

Methods of treating organic acidemias Download PDF

Info

Publication number
AU2020236023A1
AU2020236023A1 AU2020236023A AU2020236023A AU2020236023A1 AU 2020236023 A1 AU2020236023 A1 AU 2020236023A1 AU 2020236023 A AU2020236023 A AU 2020236023A AU 2020236023 A AU2020236023 A AU 2020236023A AU 2020236023 A1 AU2020236023 A1 AU 2020236023A1
Authority
AU
Australia
Prior art keywords
coa
alkyl
acid
pharmaceutically acceptable
acidemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020236023A
Other languages
English (en)
Inventor
Robert FIGLER
John Reardon
Brian Wamhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemoshear Therapeutics Inc
Original Assignee
Hemoshear Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemoshear Therapeutics Inc filed Critical Hemoshear Therapeutics Inc
Publication of AU2020236023A1 publication Critical patent/AU2020236023A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020236023A 2019-03-14 2020-03-13 Methods of treating organic acidemias Abandoned AU2020236023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818372P 2019-03-14 2019-03-14
US62/818,372 2019-03-14
PCT/US2020/022760 WO2020186216A1 (en) 2019-03-14 2020-03-13 Methods of treating organic acidemias

Publications (1)

Publication Number Publication Date
AU2020236023A1 true AU2020236023A1 (en) 2021-11-04

Family

ID=72426817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020236023A Abandoned AU2020236023A1 (en) 2019-03-14 2020-03-13 Methods of treating organic acidemias

Country Status (11)

Country Link
US (1) US20220142955A1 (https=)
EP (1) EP3937922A4 (https=)
JP (1) JP2022525339A (https=)
KR (1) KR20210139274A (https=)
CN (1) CN113557014A (https=)
AU (1) AU2020236023A1 (https=)
BR (1) BR112021018036A2 (https=)
CA (1) CA3133260A1 (https=)
EA (1) EA202192497A1 (https=)
IL (1) IL285822A (https=)
WO (1) WO2020186216A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216848A1 (en) * 2021-04-06 2022-10-13 Hemoshear Therapeutics, Inc. Methods of treating methylmalonic acidemia and propionic acidemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249706B (it) * 1991-09-18 1995-03-09 Sigma Tau Ind Farmaceuti Uso di l-carnitina nella gravidanza a rischio.
AU3889197A (en) * 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
US20050027006A1 (en) * 2003-07-28 2005-02-03 Reuben Matalon Methods and materials for treating conditions associated with metabolic disorders
WO2011072086A1 (en) * 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20120289476A1 (en) * 2009-12-11 2012-11-15 Jay Allan Barth Methods for treating methylmalonic acidemia
US9018176B2 (en) * 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
ES2795798T3 (es) * 2011-07-06 2020-11-24 Ptc Therapeutics Inc Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas
EP2877444B1 (en) * 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US20180064154A9 (en) * 2015-09-01 2018-03-08 D. Holmes Morton Management of propionate metabolism disorders
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
WO2017139697A1 (en) * 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2017184583A1 (en) * 2016-04-19 2017-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism

Also Published As

Publication number Publication date
IL285822A (en) 2021-10-31
EP3937922A4 (en) 2022-11-30
CA3133260A1 (en) 2020-09-17
EP3937922A1 (en) 2022-01-19
JP2022525339A (ja) 2022-05-12
US20220142955A1 (en) 2022-05-12
WO2020186216A1 (en) 2020-09-17
CN113557014A (zh) 2021-10-26
BR112021018036A2 (pt) 2021-11-23
KR20210139274A (ko) 2021-11-22
EA202192497A1 (ru) 2021-11-18

Similar Documents

Publication Publication Date Title
US20220267780A1 (en) Conjugates of bile acids and their derivatives for active molecules delivery
US20190022247A1 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11578032B2 (en) Derivatives of sobetirome
BR112017021522B1 (pt) Composto, composição farmacêutica e usos de compostos
US20210102006A1 (en) Cyclodextrin based polymers, methods, compositions and applications thereof
BR112016005601B1 (pt) composto, composição farmacêutica, e usos de um composto
AU2020236023A1 (en) Methods of treating organic acidemias
CN103889408A (zh) S1p受体调节剂或激动剂的剂量方案
EP3189033B1 (en) Pharmaceutical compounds
CN102344950B (zh) 一种用于检测ssat底物的乙酰化代谢物的方法
AU2021361997A1 (en) Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders
BR112021007684A2 (pt) cocristal, composição farmacêutica, métodos para tratar uma doença ou distúrbio que se beneficiaria da modificação da cadeia de transporte de elétrons, para reduzir os níveis de triglicerídeos, para tratar uma doença ou distúrbio selecionado a partir do grupo que consiste em uma síndrome metabólica, diabetes tipo ii, uma hiperlipidemia congênita e hiperlipidemia induzida por drogas, para tratar uma condição relacionada à disfunção mitocondrial, para melhorar o desempenho esportivo, resistência, construção de forma ou força muscular, ou facilitar a recuperação dos efeitos do treinamento ou competição e para tratar ou prevenir distrofinopatia, sarcoglicanopatia ou disferlinopatia, processo para preparar um cocristal, e, uso de um cocristal
TW201400447A (zh) ３－（１５－羥基十五烷基）－２，４，４－三甲基－２－環己烯－１－酮之共結晶
CN110117302A (zh) 神经退行性疾病的治疗药物及其应用
CA2965898C (en) Fatty acid analogs
Ishigaki et al. Fukuyama congenital muscular dystrophy: clinical features and therapeutic advances
US20240366543A1 (en) Methods of treating methylmalonic acidemia and propionic acidemia
CN113402444A (zh) 一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用
RU2806794C2 (ru) Производные собетирома
CN118530166A (zh) 氮杂二苯乙烯类化合物及在代谢综合征防治中的应用
CN120208950A (zh) 一种小檗碱盐及其应用
WO2023154412A1 (en) Anti-inflammatory compounds, pharmaceutical compositions, and treatment methods
US20230192638A1 (en) Polyphenols derivatives
CN120584098A (zh) 用于治疗镰状细胞病的具有直接聚合物失稳效应的苯甲醛化合物
EP2329824A1 (en) Novel pharmaceutical composition for treatment of nociceptive pain

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period